Wednesday
Pharma Webinars
Oct. 28th
1
11:00 am – 12:15 pm ET
The ability to claim larger health system productivity benefits from the introduction of chronic disease medicines looms in importance as these therapeutic segments become more crowded and competitive.
Category: Chronic Diseases
Moderator:
Katherine Vandebelt
Global Vice President, Clinical Innovation
Oracle Health Science
See here :
Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG
WHO IS SPEAKING
Douglas Schlichting, RN, PhD
Development Director
Immunology Product Development – baricitinib rheumatoid arthritis and COVID-19
Eli Lilly and Company
David Platt, MD
Vice President, Medical Unit Head
Cardiovascular, Renal & Metabolism Medical Unit
Novartis Pharmaceuticals Corporation
Dr. Sandi See Tai
VP, Medicine Team Lead for Amyloid, Rare Neuro & Cardiac
Pfizer Global Product Development
Pfizer Inc.
Sailaja Bhaskar, BPharm, MS, PhD, MBA
Executive Director, Clinical Operations Planning
Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P.
Eric M Pearlman
Senior Medical Director-Neuroscience, US Medical Affairs
Eli Lilly and Company
2
12:30 pm – 1:45 pm ET
What are the prospects – and limitations – behind the new approaches to cancer treatments from our increased knowledge of the underlying biology behind tumor growth and proliferation?
Category: Solid Tumor Cancers
Moderator:
Theodore F. Search, MD
Chief Executive Officer
Skipta
See here :
Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG
Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG
WHO IS SPEAKING
Sam Spigelman, MD
Senior Global Medical Affairs Leader
Janssen Research & Development, LLC
Sabine Brookman-May, MD, PhD
Executive Medical Director, Late Development, Solid Tumor
Janssen Research & Development, LLC
Ted W. Johnson, PhD
Research Fellow
Medicinal Chemistry, Pfizer Oncology
Pfizer Inc.
3
2:00 pm – 3:00 pm ET
Are there common links in advancing research on hematologic cancers and other rare diseases associated with uncontrolled vascular system inflammation, such as sickle cell anemia?
Category: Hematologic cancers and other rare diseases
Moderator:
Theodore F. Search, MD
Chief Executive Officer
Skipta
See here :
Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG
Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG
WHO IS SPEAKING
Ramon V. Tiu, MD
Executive Medical Director, Astellas Pharma Global Development
Global Medical Leader, Gilteritinib Program
Astellas Pharma Inc.
Dr. Michael G. Kauffman, MD, PhD
Chief Executive Officer
Co-Founder
Karyopharm Therapeutics Inc.
4
3:00 pm – 4:00 pm ET
Will the coronavirus pandemic finally lead to an upswing in R&D to tackle neglected areas like antibiotic resistance, zoonotic transmission of pathogens and a more globally-coordinated approach to infectious diseases overall?
Category: Infectious diseases and reproductive health
Moderator:
MaryAnne Rizk, PhD
Senior Vice President, R&D Digital Strategy
IQVIA
See here :
Moderator: Lorem Ipsum, Clinical Research Consultants and HumanOptics AG, Clinical Research Consultants and HumanOptics AG
WHO IS SPEAKING
Mark Sullivan
Founder and Managing Director
Medicines Development for Global Health
Amanda Paschke, MD, MSCE
Executive Director
Global Clinical Development
Merck & Co., Inc.
